We therefore contend that in cancers associated with production of GCSF, normalization of GCSF levels or GCSFR signaling may enhance antitumor immunity either alone or in conjunction with immune checkpoint blockade or adoptive T-cell therapy. This evidence concerns the gene CSF3 and cancer.